AtriCure, Inc. (NASDAQ:ATRC) Shares Sold by TD Asset Management Inc.
AtriCure, Inc. (NASDAQ:ATRC) Shares Sold by TD Asset Management Inc.
TD Asset Management Inc. decreased its position in AtriCure, Inc. (NASDAQ:ATRC – Get Rating) by 27.5% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 57,817 shares of the medical device company's stock after selling 21,888 shares during the quarter. TD Asset Management Inc. owned 0.12% of AtriCure worth $3,797,000 as of its most recent SEC filing.
据TD Asset Management Inc.在提交给美国证券交易委员会的最新文件中称，该公司第一季度将其在AtriCure，Inc.(纳斯达克代码：ATRC-GET Rating)的持仓减少了27.5%。该机构投资者在本季度出售了21,888股后，持有这家医疗器械公司57,817股股票。截至最近提交的美国证券交易委员会申报文件，TD Asset Management Inc.持有AtriCure 0.12%的股份，价值3，79.7万美元。
Several other hedge funds also recently made changes to their positions in ATRC. Pinebridge Investments L.P. acquired a new position in shares of AtriCure in the 4th quarter worth approximately $56,000. First Horizon Advisors Inc. lifted its holdings in shares of AtriCure by 80.5% in the 4th quarter. First Horizon Advisors Inc. now owns 1,496 shares of the medical device company's stock worth $103,000 after purchasing an additional 667 shares during the last quarter. Islay Capital Management LLC bought a new stake in shares of AtriCure in the 1st quarter worth approximately $117,000. Rockefeller Capital Management L.P. lifted its holdings in shares of AtriCure by 10.1% in the 4th quarter. Rockefeller Capital Management L.P. now owns 2,341 shares of the medical device company's stock worth $162,000 after purchasing an additional 215 shares during the last quarter. Finally, Ensign Peak Advisors Inc bought a new stake in shares of AtriCure in the 4th quarter worth approximately $203,000. Institutional investors and hedge funds own 95.36% of the company's stock.
其他几家对冲基金最近也改变了他们在ATRC的头寸。PineBridge Investments L.P.在第四季度收购了AtriCure股票的新头寸，价值约56,000美元。First Horizon Advisors Inc.在第四季度增持了80.5%的AtriCure股票。First Horizon Advisors Inc.现在持有这家医疗设备公司1,496股股票，价值10.3万美元，该公司在上个季度又购买了667股。Islay Capital Management LLC在第一季度购买了AtriCure的新股份，价值约11.7万美元。洛克菲勒资本管理公司(Rockefeller Capital Management L.P.)在第四季度增持了AtriCure股票10.1%。洛克菲勒资本管理公司(Rockefeller Capital Management L.P.)在上个季度额外购买了215股洛克菲勒股票后，现在持有这家医疗设备公司2,341股股票，价值162,000美元。最后，Ensign Peak Advisors Inc.在第四季度购买了AtriCure价值约203,000美元的新股。机构投资者和对冲基金持有该公司95.36%的股票。
Analyst Upgrades and Downgrades
分析师升级和下调评级
Several analysts recently issued reports on ATRC shares. Stifel Nicolaus cut their price target on AtriCure from $70.00 to $50.00 in a report on Monday, July 18th. StockNews.com downgraded AtriCure from a "hold" rating to a "sell" rating in a research note on Tuesday. Piper Sandler cut their target price on AtriCure from $90.00 to $55.00 and set an "overweight" rating on the stock in a research note on Wednesday, August 3rd. Needham & Company LLC lifted their target price on AtriCure from $55.00 to $65.00 and gave the company a "buy" rating in a research note on Wednesday, August 3rd. Finally, BTIG Research cut their target price on AtriCure from $94.00 to $75.00 and set a "buy" rating on the stock in a research note on Friday, June 24th. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the company's stock. According to MarketBeat, AtriCure currently has a consensus rating of "Moderate Buy" and an average price target of $75.86.
几位分析师最近发布了有关ATRC股票的报告。Stifel Nicolaus在7月18日星期一的一份报告中将AtriCure的目标价从70.00美元下调至50.00美元。周二，StockNews.com在一份研究报告中将AtriCure的评级从持有下调至卖出。派珀·桑德勒在8月3日(周三)的一份研究报告中将AtriCure的目标价从90.00美元下调至55.00美元，并对该股设定了“增持”评级。8月3日，Needham&Company LLC在一份研究报告中将AtriCure的目标价从55.00美元上调至65.00美元，并给予该公司“买入”评级。最后，BTIG Research将AtriCure的目标价从94.00美元下调至75.00美元，并在6月24日(星期五)的一份研究报告中设定了该股的“买入”评级。一名研究分析师对该股的评级为卖出，五名分析师对该公司股票的评级为买入。根据MarketBeat的数据，AtriCure目前的普遍评级为“适度买入”，平均目标价为75.86美元。
AtriCure Trading Down 4.7 %
AtriCure股价下跌4.7%
AtriCure (NASDAQ:ATRC – Get Rating) last announced its earnings results on Tuesday, August 2nd. The medical device company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.30) by ($0.02). AtriCure had a negative return on equity of 11.47% and a net margin of 17.62%. During the same period last year, the business earned ($0.30) EPS. On average, equities analysts forecast that AtriCure, Inc. will post -1.09 EPS for the current fiscal year.
AtriCure(纳斯达克代码：ATRC-GET Rating)最近一次公布财报是在8月2日星期二。这家医疗设备公司公布了该季度每股收益(EPS)(0.32美元)，低于分析师普遍预期的(0.30美元)和(0.02美元)。AtriCure的股本回报率为负11.47%，净利润率为17.62%。去年同期，该业务每股收益为0.30美元。股票分析师平均预测，AtriCure，Inc.本财年每股收益将为1.09欧元。
AtriCure Profile
AtriCure配置文件
(Get Rating)
(获取评级)
AtriCure, Inc develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation.
AtriCure公司为美国、欧洲、亚洲和国际的医疗中心开发、制造和销售心脏组织和系统以及肋间神经的外科消融设备。该公司提供一次性射频产品Isolator Synergy Clip；多功能笔和线性消融设备，如Max Pen设备，使外科医生能够使用相同的设备评估心律失常、执行临时心脏起搏、传感和刺激并消融心脏组织；以及Coolail设备，使用户能够进行更长的线性消融。
Recommended Stories
推荐故事
- Get a free copy of the StockNews.com research report on AtriCure (ATRC)
- Why This Dip in Advanced Auto Parts May be an Opportunity
- MarketBeat: Week in Review 8/22 – 8/26
- Institutional Buying Put A Bottom In Marvell Technology
- Dell Stock Retreats On Weaker Sales, Falls Into Value Terrirtory
- 3 Reasons Dollar General's Rally Has Legs
- 免费获取StockNews.com关于AtriCure的研究报告(ATRC)
- 为什么进军高级汽车零部件可能是一个机会
- MarketBeat：回顾中的一周8/22-8/26
- 机构买入让Marvell科技陷入低谷
- 戴尔股票因销售疲软而回落，跌入可怕的价值
- Dollar General的拉力赛有三个理由
Want to see what other hedge funds are holding ATRC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AtriCure, Inc. (NASDAQ:ATRC – Get Rating).
想看看其他对冲基金持有ATRC吗？访问HoldingsChannel.com获取AtriCure，Inc.(纳斯达克代码：ATRC-GET Rating)的最新13F备案文件和内幕交易信息。
Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.
接收AtriCure日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对AtriCure和相关公司的最新新闻和分析师评级的每日简要摘要。